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Background: Surface CD157 modulates leukocyte and ovarian cancer cell adhesion and migration through the interaction
with an unknown ligand.
Results: CD157 binds heparin-binding domains of numerous extracellular matrix proteins with high affinity.
Conclusion: The interaction of CD157 with extracellular matrix proteins is instrumental in the regulation of cell adhesion.
Significance: These findings provide valuable insights into the biological mechanism responsible for the nonenzymatic func-
tions of CD157.
CD157/BST-1 behaves both as an ectoenzyme and signaling
receptor and is an important regulator of leukocyte trafficking
and ovarian cancer progression. However, the molecular inter-
actions underpinning the role of CD157 in these processes
remain obscure. The biological functions of CD157 and its part-
nership with members of the integrin family prompted us to
assume the existence of a direct interaction betweenCD157 and
anunknowncomponent of the extracellularmatrix.Using solid-
phase binding assays and surface plasmon resonance analysis,
we demonstrated that CD157 binds fibronectin with high affin-
itywithin its heparin-binding domains 1 and2. Furthermore,we
found that CD157 binds to other extracellular matrix proteins
containing heparin-binding domains. Finally, we proved that
the CD157-fibronectin interaction occurs with living cells,
where it elicits CD157-mediated cell responses. Indeed, knock-
down of CD157 in Met-5A mesothelial cells changed their
morphology and cytoskeleton organization and attenuated
the activation of intracellular signaling pathways triggered by
fibronectin. This led to impaired cell spreading and adhesion to
selected extracellular matrix proteins. Collectively, these find-
ings indicate a central role of CD157 in cell-extracellularmatrix
interactions andmakeCD157 an attractive therapeutic target in
inflammation and cancer.
Ectoenzymes are a large and heterogeneous class of cell sur-
face-expressed enzymes (1). Many are expressed in leukocytes
and endothelial cells, where they modulate each step of leuko-
cyte trafficking (2). In recent years, we have focused our atten-
tion on CD157/BST-1, a glycosylphosphatidylinositol-an-
chored glycoprotein belonging to the ADP-ribosyl cyclase gene
family (3). CD157 is expressed in myeloid, endothelial, and
mesothelial cells and in epithelial ovarian cancer cells (4, 5).
Since its discoverymore than 20 years ago, humanCD157 (then
known asMo5) (6) has been implicated in the control of leuko-
cyte migration (7). Subsequently, leukocyte CD157 was found
to control adhesion to extracellular matrix (ECM)4 proteins,
directional migration, and diapedesis (8, 9) by establishing
structural and functional interactions with specific members of
the integrin family of adhesion receptors (10, 11). Evidence
obtained by in vitro experiments and from correlative clinical
studies in ovarian cancer patients suggested an important func-
tional link between high expression of CD157 and the malig-
nant phenotype of tumor cells, including their increasedmotil-
ity and invasion of surrounding tissues (12). It became clear that
CD157 could induce a variety of cellular responses both in leu-
kocytes and in ovarian cancer cells, including changes in mor-
phology, spreading, adhesion, motility, and transmigration.
These activities of CD157 are apparently unrelated to its enzy-
matic functions (13–15). So far, the efforts to unravel the non-
enzymatic functions of CD157 have been hampered by the lack
of a known nonsubstrate ligand, whose identification has
proved elusive. This limitation was partially overcome by the
use of specific monoclonal antibodies, a strategy commonly
adopted tomimic the effects of putative ligands. This approach
consistently pointed to an important role ofCD157 in cell adhe-
sion and migration, but it failed to identify which interactions
were instrumental for its receptor activities in normal and path-
ological conditions. The crucial role of CD157 in cell adhesion,
migration and invasion, and its functional partnership with
members of the integrin family inmyeloid cells (11) fostered the
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hypothesis that the ligand of CD157 might be found in the
ECM.
The ECM is a complex network of proteins and polysaccha-
rides that is secreted, assembled, and modeled by cells. The
ECM constitutes the complex structural scaffold surrounding
and supporting cells in all tissues andorgans, enablingmicroen-
vironmental sensing. The dynamic regulation of cell-ECM
interactions is essential for the successful outcome of physio-
logical processes, including embryonic development, morpho-
genesis and tissue homoeostasis (16). Conversely, aberrant cell-
ECM interactions underlie many diseases; for example, the
pathogenesis of inflammatory diseases relies on aberrant cell
aggregation and/or migration, whereas altered adhesion is a
defining characteristic of malignancy (17).
ECM proteins are large and complex and are highly con-
served in animal taxa. By virtue of their ordered domain orga-
nization, ECM proteins orchestrate the juxtaposition of differ-
ent receptors, generating multimolecular complexes in the
plasma membrane (18). In mammalian cells, the interaction
between cells and ECM is coordinated primarily by the mem-
bers of two gene families, integrins and syndecans (19). These
mediate cell-ECM adhesion and regulate intracellular signaling
pathways that drive cell proliferation, differentiation, migra-
tion, and survival. Integrins and syndecans are flanked by awide
variety of cell surface proteins that bind to specific domains
within selected ECM proteins.
In this study, using solid-phase binding assays and surface
plasmon resonance (SPR) biosensor, we assessed the possible
interactions between CD157 and fibronectin, a prototypic
ECM protein that plays a central role in cell adhesion, migra-
tion, and differentiation (20).
EXPERIMENTAL PROCEDURES
Proteins and Antibodies—Human plasma fibronectin (FN)
and its proteolytic fragments (30 and 45 kDa, corresponding to
the heparin (HBD1) and gelatin- and collagen (GBD)-binding
domains, respectively), laminin-1 (LM), collagen type I (Coll I),
vitronectin (Vn), heparin, human plasma fibrinogen (FB),
fibrin, hyaluronic acid, and BSA were purchased from Sigma.
The 120- and 40-kDa proteolytic fragments from FN, e.g. the
cell-binding domain (CBD) and the heparin-binding domain 2
(HBD2), were fromChemicon (Millipore,Milan, Italy). Recom-
binant His-tagged human soluble CD157 (rh-sCD157, 4736-
AC-050) and PDGF receptor  (rh-PDGFR, 322-PR-050),
both produced inNS0-derivedmousemyeloma cells, were pur-
chased from R&D Systems (Milan, Italy). Bacterial recombi-
nant His-tagged human CD157 (b-rhCD157, MBS2010989)
was from MyBiosources (Aurogene, Rome, Italy). Anti-CD157
(SY/11B5, IgG1), anti-1 integrin/CD29 (Moon-4, IgG1),
monoclonal antibodies (mAb), and irrelevantmurinemonoclo-
nal IgG (mIgG) (produced in-house) were affinity-purified on
protein G (Sigma). RF3 (anti-CD157, IgG2a) mAb was pur-
chased from MBL International (Milan, Italy); Mo5 (anti-
CD157, IgG2a) mAb was kindly provided by R. Todd III (Uni-
versity of Michigan Health System, Ann Arbor, MI). Anti-v
integrin/CD51 (NKI-M9) blocking mAb, HRP-conjugated
donkey anti-sheep, goat anti-rabbit, and goat anti-mouse poly-
clonal antibodies, and HRP-conjugated anti--actin antibody
were purchased from Santa Cruz Biotechnology (Milan, Italy).
Anti-human CD157 affinity-purified polyclonal IgG produced
in sheep were from R&D Systems. Affinity-purified FITC-la-
beled F(ab)2 fraction from goat antibodies to rabbit IgG was
from Jackson ImmunoResearch (LiStarfish, Milan, Italy).
TRITC-labeled phalloidin used to detect F-actin was obtained
from Sigma.
Cell Line and Transduction—Met-5A nonmalignant pleural
mesothelial cell line was purchased from American Type Cul-
ture Collection (ATCC, Manassas, VA) and maintained in
RPMI 1640 medium supplemented with 10% FCS. CD157
expression was silenced by lentiviral delivery of short hairpin
RNA (shRNA) targeting BST-1 mRNA (target sequences
5-GAGTCAGACTGCTTGTATA-3 (shCD157) and scram-
ble sequence 5-TTCTCCGAACGTGTCACGTT-3) as de-
scribed previously (15, 21). Transduced cells were selected in 2
g/ml puromycin (Santa Cruz Biotechnology) for 3 days.
Solid-phase Binding Assay—Solid-phase binding assays were
performed in 96-well microtiter plates (Nunc MaxiSorp) by
ELISA. Wells were coated overnight at 4 °C with 50 l/well of
10 g/ml of the indicated matrix proteins or fibronectin frag-
ments and blocked with 0.1% BSA and 0.05% Tween 20 for 2 h
at 37 °C. Following two washes with PBS containing 0.1%
Tween 20, rh-sCD157 was added at the indicated concentra-
tions and incubated for 2 h at 37 °C. Bound proteins were
detected by specific sheep anti-CD157 polyclonal antibody (1 h
at 37 °C), followed by HRP-conjugated anti-sheep IgG poly-
clonal antibody (1 h at 37 °C). The peroxidase substrate
3,3,5,5-tetramethylbenzidine (Sigma) was added to the wells
for 10 min; the reaction was stopped with H2SO4 (0.5 M), and
the absorbance was measured at 450 nm using a microplate
reader.
In competition experiments, rh-sCD157 (100 ng/ml) was
preincubated for 20min at room temperature with 10g/ml of
the indicated anti-CD157 mAb or isotype-matched IgG and
then was added to the wells. In binding inhibition assays, rh-
sCD157 (100 ng/ml) was preincubated with fibrin, heparin, or
hyaluronic acid at the indicated concentrations.
Surface Plasmon Resonance—The carboxylate cuvettes, N-
hydroxysuccinimide, 1-ethyl-3-(3-dimethylaminopropyl)car-
bodiimide, and ethanolamine, were obtained from Neosensors
(Crewe, UK). Biosensor analyses were performed on an IAsys
plus device (Affinity Sensors, Cambridge, UK). The carboxylate
cuvette was thermostatted at 25 °C, and impurities were
removed by washing with PBS-T (0.05% Tween 20). Prior to
activation, the carboxylate surface was washed with detergent-
free PBS to ensure the establishment of a base line for the sensor
trace at the set temperature and to avoid the “mask” effect of
carboxyl groups due to the presence of the detergent. Surface
carbonyl groups were activated with 7 min of incubation with
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-hydroxy-
succinimide (freshly prepared by mixing v/v 100 mM N-
hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide solutions) (35). Each protein to be immobilized
was dissolved in 10mMCH3COONa (300g/ml), at the proper
pH, which was chosen on the basis of the isoelectric point (e.g.
7.7 for FN, 9.7 for HBD1, 5.5–6 for HBD2, and 4.9 for CBD). In
detail, we used pH 5 for full-length FN, pH 6 for HBD1 and
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HBD2, and pH 4.5 for CBD. Finally, each protein was anchored
to the carboxylic surface via nucleophilic attack of their N ter-
minus to the activated carbonyl groups. After 20 min of incu-
bation, noncoupled ligand was removed by PBS washes. Free
carboxyl groups were inactivated, and any electrostatically
boundmaterial was removed by 1 M ethanolamine. The surface
was finally re-equilibrated with PBS. These conditions were
found to best suit an optimal immobilization of the proteins
without affecting their functional properties. For each surface, a
normally distributed population of the immobilized protein in
the monolayer was obtained by repeating spot-sampling at dif-
ferent sites (n 10) on the biosensor surface (data not shown).
rh-sCD157 and b-rhCD157 were independently added at the
indicated concentrations, and binding kinetics were followed
up to equilibrium. Dissociation steps and surface regeneration
were performed by addition of PBS. Binding was measured at
5-s intervals. Binding datawere analyzed by using the Fast Fit soft-
ware (Fison Applied Sensor Technology). In reverse binding ex-
periments, rh-sCD157 was dissolved (300 g/ml) in 10 mM
CH3COONa, pH 5, and incubated for 20 min on a 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide-ac-
tivated carboxylate surface to a final surface density of 1.4 ng
mm2.Next, interactionexperimentswereperformedbyaddition
of either soluble HBD1, HBD2, or FN, as described above.
SDS-PAGE and Western Blot Analysis—rh-sCD157 and
b-rhCD157 (1g) were run on 10% SDS-PAGE under reducing
and nonreducing conditions and stained with Coomassie Bril-
liant Blue. For Western blot analysis, total cell lysates were
obtained by incubation of cells in RIPA lysis buffer (50 mM
Tris-HCl, 150mMNaCl, 1%Nonidet P-40, 0.5% sodium deoxy-
cholate, 1 mM EDTA, 0.1% SDS) supplemented with 50 g/ml
aprotinin and leupeptin. Protein concentrationwas determined
using the Bradford assay (Bio-Rad). Protein extracts (30 g)
were separated by 10% SDS-PAGE under nonreducing condi-
tions and transferred onto a PVDF membrane (Millipore,
Milan, Italy). The membrane was blocked with 5% milk and
probed with the SY/11B5 anti-CD157 mAb, followed by HRP-
conjugated anti-mouse IgG. The immunoreactive bands were
visualized using the ECL detection system (Cyanagen, Bologna,
Italy). Images were captured with a ChemiDocTM XRS sys-
tem, and densitometry analysis was performed with Image-
LabTM software (Bio-Rad).
Immunofluorescence and Confocal Microscopy—For FACS
analysis, cells (2  105/sample) were incubated for 30 min at
4 °C with 5 g/ml of the indicated antibody, washed, and incu-
bated for 30 min at 4 °C with F(ab)2 GMIg-FITC. Fluores-
cencewas determined using a FACSCalibur flow cytometer and
analyzed with CellQuest software (BD Biosciences). Back-
ground mAb binding was estimated by means of an isotype-
matched negative controlmAb. Ten thousand eventswere con-
sidered for each analysis.
For confocal microscopy analysis, glass coverslips were
coated with FN (10 g/ml) and blocked with 1% BSA. Cells
were preincubated with cycloheximide (20 g/ml, Sigma) for
2 h in serum-free medium, detached with EDTA, and plated on
FN-coated coverslips (1  105/well) for 4 h in the presence of
cycloheximide to prevent synthesis of endogenousmatrix. Cells
were washed, fixed with 2% paraformaldehyde (PFA), permea-
bilized with 0.2% Triton X-100, and stained with TRITC-la-
beled phalloidin. Samples were analyzed using an Olympus
FV300 laser scanning confocal microscope (Olympus, Milan,
Italy) and imaged using a60 oil immersion objective (1.4NA).
RNA Extraction and RT-PCR—Total RNA (2 g) was
extracted from 70 to 80% confluent cultures using TRI Reagent
(Sigma) and reverse-transcribed with theMoloney murine leu-
kemia virus reverse transcriptase (Invitrogen) and oligo(dT)
primers. cDNA was amplified using KAPA2G Fast HotStart
DNA polymerase (Kapa Biosystems, Cambridge,MA). Each cycle
consisted of denaturation at 95 °C for 10 s, annealing for 10 s, and
extension at 72 °C for 1 s. The primers used were as follows:
CD157, 5-CCAAAGTTCCCCGATGGCGGCC-3 (forward)
and 5-GGTTAGAGCAACACAGTTTCC-3 (reverse); -actin,
5-CCAAGGCCAAACCGCGAGAAGATGAC-3 (forward) and
5-AGGGTACATGGTGGTGCCGCCAGAC-3 (reverse). PCR
products were analyzed by electrophoresis on 1% agarose gel
stained with ethidium bromide (Sigma).
Cell Adhesion Assays—Met-5A cells (3  104 in serum-free
medium) were plated onto 96-well plates coated with the indi-
cated ECM protein or FN fragment (10 g/ml) and blocked
with 2% BSA. Cells were incubated for 30 min (or 2 h on FN
domains) at 37 °C, and then nonadherent cells were removed;
adherent cells were fixed with 4% PFA and stained with 0.5%
crystal violet.Where indicated, cells were pretreated for 20min
with 10g/ml anti-CD157, anti-CD29, or anti-CD51mAbs or an
isotype-matched irrelevant IgG. In binding competition studies,
ECM-coatedwells were saturated for 1 h at 37 °Cwith rh-sCD157
(100ng/ml).Adherentcellswereassessedby lightmicroscopy, and
five randomly selected fields (4) for each well were photo-
graphed and counted. Each conditionwas carried out in triplicate,
and experiments were repeated at least three times.
Phosphorylation Assays—Met-5A cells were serum-starved
overnight, detached with 2 mM EDTA in PBS, suspended in
serum-freemedium (1 106/ml), and allowed to recover for 30
min at 37 °C. Then 1ml of cell suspensionwas plated ontowells
coated with FN (5 g/ml) and blocked with heat-denatured
BSA 1% in PBS. After 1 h of adhesion, cells were placed on ice,
washedwith ice-cold RPMI 1640medium supplementedwith 1
mMpervanadate to stop the reaction, and lysed in ice-coldRIPA
buffer. Total lysates (20 g/lane) were run on 10% SDS-PAGE
under reducing conditions and transferred onto PVDF mem-
branes. After blocking, membranes were probed with anti-
phospho-c-SRC (Tyr-530), anti-phospho-FAK (Tyr-397) or anti-
phospho-Akt (Ser-493) (Santa Cruz Biotechnology), stripped,
and re-probed with anti-c-SRC, anti-FAK, anti-Akt1 mAbs
(Santa Cruz Biotechnology), followed by incubation with the
appropriate HRP-conjugated antibodies. Specific bands were
visualized by ECL and captured with a ChemiDoc analyzer, and
densitometry analysis was performed with ImageJ software
(National Institutes of Health, Bethesda).
Statistical Analysis—Individual experiments were per-
formed at least in triplicate, and unless otherwise stated, the
data presented are themeans S.E. of 3–4 independent exper-
iments. Comparisons between two groups were carried out
using an unpaired Student’s t test for normal distributed vari-
ables. Comparisons between three or more groups were per-
formed with one-way ANOVA analysis with Dunnett’s or Bon-
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ferroni post-test. Statistical analysis was performed using
GraphPad Prism 5 software (SanDiego). For all analyses, differ-
enceswere considered significant at p 0.05 (*,p 0.05; **,p
0.01; ***, p 0.001 versus control).
RESULTS
CD157 Binds to Fibronectin—We developed a solid-phase
immunoenzymatic assay based on the binding of rh-sCD157
produced in mammalian cells (Fig. 1A) to microtiter plates
coated with selected human ECM proteins or BSA as control.
We first focused on fibronectin, a ubiquitous component of the
ECM that plays a crucial role in mediating cell attachment,
because of previous evidence underscoring a functional and
structural partnership between CD157 and 1 (and 2) integ-
rin, which are elective receptors for fibronectin (11). Purified
rh-sCD157 displayed concentration-dependent binding to FN.
His-tagged rh-PDGFR, used as a specificity control protein,
did not bind to FN (Fig. 1B). To further corroborate the speci-
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FIGURE1. rh-sCD157bindsfibronectin.A,SDS-PAGEofhumanrecombinantsCD157produced inmurinemyelomaNS0-derivedcells.Purified rh-sCD157rununder
nonreducing and reducing conditions was detected as 38–40-kDa bands. rh-sCD157 was denatured by boiling 10 min with 0.2% (w/v) SDS in sodium phosphate
buffer, pH 7.5, and incubated for 3 h at 37 °C with 1 unit of peptide N-glycosidase F (PNGase F) (Sigma), according to themanufacturers’ protocol. The reaction was
stopped by heating at 100 °C for 5 min, and samples were suspended in Laemmli Sample Buffer and run on SDS-PAGE. The molecular weight of rh-sCD157 after
peptideN-glycosidaseF treatmentwasconsistentwith thepredictedmolecularweightof31kDabasedon thededucedaminoacid sequence.MW,molecularweight
markers (PrecisionPlusProteinAll Blue standards, Bio-Rad);NR,nonreducingconditions;R, reducingconditions.B, concentration-dependentbindingof rh-sCD157 to
immobilizedFNanalyzedbysolid-phasebindingassay.Microtiterplatescoatedwith10g/mlFNorBSAwere incubatedwith increasingconcentrationsof rh-sCD157
or rh-PDGFR (6.25–400 ng/ml), used as control. Matrix-bound rh-sCD157 or rh-PDGFRwas assessed by anti-CD157 or anti-PDGFRpolyclonal antibody, followed
by HRP-labeled anti-rabbit IgG. The mean S.D. of one representative experiment performed in triplicate is shown (n 3). The best fits for FN (solid line) and BSA
(dashed line) are shown. O.D. optical density. C, inhibition of rh-sCD157 binding to FN by anti-CD157 mAbs. The indicated mAb or murine monoclonal IgGs (10
g/ml)were incubatedwith 100ng/ml of rh-sCD157 for 20min at room temperature, and rh-sCD157bindingwas analyzed. Results are expressed as relative ratio to
the absorbance of rh-sCD157 without inhibitors (100%, white histogram). The mean S.E. of three independent experiments is shown. **, p 0.01, ANOVA with
Dunnett’smultiple comparison test.D, schematic representationof themodular structure of one chainof thedimeric human fibronectin.Rectangles represent type I;
diamonds represent type II, and ovals represent type III motifs. These structural motifs include 12 FN type I repeats (FN1), 2 FN type II repeats (FN2), 15 constitutively
expressed and 2 alternatively spliced FN type III (FN3) repeats, and a nonhomologous variable (V) region. Sets of adjacentmotifs formbindingdomains for a number
of proteins. The heparin- (HBD1 and HBD2), gelatin- (GBD), and cell (CBD)-binding domains generated by proteolytic cleavage and used in the solid-phase binding
assaysareunderlined.E, bindingof rh-sCD157toFNdomainsmeasuredbysolid-phasebindingassays. rh-sCD157(100ng/ml)wasaddedontomicrotiterplatescoated
with 10g/ml FN or its domains. Themean S.D. of one representative experiment is shown (n 3).Dashed line indicates significant binding over baseline (2-fold
bindingtoBSA).F, concentration-dependentbindingof rh-sCD157to immobilizedFNdomains.MicrotiterplatescoatedwithGBD,HBD1,HBD2,andCBDofFNorBSA
(10g/ml)were incubatedwith increasing concentrations of rh-sCD157 (6.25–400ng/ml). Themean S.E. of three experiments performed induplicate is shown.G
andH, inhibition of rh-sCD157 binding to HBD1 andHBD2 by anti-CD157mAbs. After incubation of the indicatedmAbs and control IgG (10g/ml) with rh-sCD157
(100 ng/ml) for 20 min at room temperature, rh-sCD157 binding to HBD1 and HBD2 was determined. Results are expressed as relative ratio to the absorbance of
rh-sCD157 in theabsenceofmAb (100%,white histogram). ThemeanS.E. of three independent experiments is shown. **,p0.01,ANOVAwithDunnett’smultiple
comparison test.
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ficity of the observed binding, the assay was repeated in the
presence of a panel of anti-CD157 mAbs. Incubation of rh-
sCD157with the RF3mAb significantly reduced binding to FN,
whereas incubation with SY/11B5 andMo5 mAbs did not (Fig.
1C). These findings argue in favor of a specific interaction
between purified CD157 and FN proteins.
CD157 Binds to FN Heparin-binding Domains—Fibronectin
is composed of three different types of structural motifs,
namely types I, II, and III motifs. Although first identified in
fibronectin (22), these motifs have since been found in other
ECM proteins. Sets of adjacent motifs form binding domains
for a variety of proteins and carbohydrates, including other FN
molecules, other ECMcomponents, heparin, fibrin, growth fac-
tors, and a dozen members of the integrin receptor family (23,
24). To identify the FN region(s) involved in the binding of
rh-sCD157, microtiter plates were coated with FN fragments
obtained by proteolytic cleavage of the full-length protein as
follows: the N-terminal 30-kDa HBD1; the 45-kDa GBD; the
120-kDa CBD containing the integrin-binding motif; and the
C-terminal 40-kDa HBD2 containing the high affinity heparin-
binding site (Fig. 1D). The solid-phase binding assays showed
that rh-sCD157 (100 ng/ml) was able to bind both HBD1 and
HBD2. Conversely, no measurable binding to GBD and CBD
fragmentswas observed (Fig. 2,E and F). Aswith full-length FN,
rh-sCD157 binding to both HBD1 and HBD2 was concentra-
tion-dependent (Fig. 1F). This binding was significantly inhib-
ited by the RF3 mAb, whereas Mo5 and SY/11B5 mAbs were
unable to significantly interfere with CD157-HBD1 or CD157-
HBD2 interactions (Fig. 1, G and H). Collectively, these data
indicate that rh-sCD157 has two binding sites in FN, located
within its N-terminal (HBD1) andC-terminal (HBD2) heparin-
binding domains, respectively. The CD157-HBD interactions
likely involve the CD157 epitope recognized by the RF3 mAb.
CD157 Binding to FN Is Prevented by Heparin—The N-ter-
minal HBD1 consists of five type I (FN1) homologous repeats
that form two distinct regions, theN-terminal FN1(1–3) region
containing the binding site for heparin and the FN1(4–5)
region that includes the binding site for fibrin (25) (Fig. 1D). To
map more precisely the binding site of rh-sCD157 within
HBD1, competition experiments were carried out using solid-
phase binding assays in the presence of excess amounts of
either heparin or fibrin. Binding of rh-sCD157 to insolubilized
full-length FN and HBD1 was prevented by addition of heparin
but not of fibrin, indicating that the binding site for CD157 is
within the FN1(1–3) region, close to or overlappingwith that of
heparin (Fig. 2,A andB).Next, we assessed the ability of heparin
to interfere with the interaction between rh-sCD157 and FN,
HBD1, or HBD2 by performing binding assays in the presence
of increasing concentrations of heparin (range, 0.6 to 150
g/ml). The presence of heparin inhibited the binding of rh-
sCD157 to full-length FN (Fig. 2C) and to both its heparin-
binding domains (HBD1 andHBD2) in a dose-dependentman-
ner (Fig. 2, D and E). Notably, 1.8 g/ml heparin significantly
inhibited and 50 g/ml heparin completely prevented
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FIGURE 2. Heparin inhibits binding of rh-sCD157 to fibronectin. A and B, competition experiments were carried out using rh-sCD157 (100 ng/ml) in
solid-phase binding assays to FN or HBD1, respectively, in the presence of 10 g/ml heparin, fibrin, or BSA. C–E, effect of heparin on rh-sCD157 (100 ng/ml)
binding to FN (C), HBD1 (D), and HBD2 (E) was assessed in the presence of increasing concentrations (0.6–150 g/ml) of heparin (dark gray histograms) or
hyaluronic acid (light gray histograms). Results are expressed as a relative ratio to the absorbance of rh-sCD157 without competitors (100%,white histogram).
Mean S.E. of three independent experiments is shown. Asterisks indicate significant differences of rh-sCD157 binding in the presence of each concentration
of competitor compared with untreated control (***, p 0.001; **, p 0.01; *,p 0.05, ANOVA with Dunnett’s multiple comparison test).
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rh-sCD157 binding to HBD1. At least 5.5 g/ml heparin were
required to significantly inhibit the binding of rh-sCD157 to
HBD2. These results suggest that there could be a second
CD157-binding site in HBD2 that is not blocked by heparin or
that the binding affinity between CD157 andHBD2 is very high
(likely higher than that betweenCD157 andHBD1).Hyaluronic
acid, another glycosaminoglycan abundantly expressed in the
ECM, did not perturb the binding of rh-sCD157 to FN, HBD1,
or HBD2 (Fig. 2, C-E), indicating that the inhibitory effect of
heparin is specific.
Analysis of CD157-Fibronectin Interaction by Surface Plas-
mon Resonance—The interactions between rh-sCD157 and FN
were further characterized by SPR analysis allowing real time
monitoring of binding kinetics. Sensing surfaces containing
either full-length FN or its proteolytic fragments were obtained
as described under “Experimental Procedures.” From the read-
out in the range 800–1400 arcsec, we calculated surface densi-
ties of	2.2 and 1.2 ng mm2 for full-length FN and for single
domains, respectively; these conditions globally resulted in the
coupling of a “Langmuir” partial monolayer of capturing mac-
romolecules. These protein immobilization levels (	3/5 of the
monolayer) were adequate to minimize possible steric hin-
drance or shielding effects, which could affect the analysis. For
each sensing surface, binding experiments were carried out at
increasing concentrations of rh-sCD157 (range, 20.3 nM to
1.049 M, corresponding to 710 ng/ml to 52.5 g/ml), as
indicated.
First, the interaction between rh-sCD157 and full-length
fibronectinwas analyzed, and biphasic association time courses
were observed (Fig. 3A); this behaviorwas ascribed to the ability
of rh-sCD157 to bind twodifferent sites onFNwith comparably
high affinity. Measured dissociation equilibrium constants
obtained for this interaction were KD, 1  60  29 nM and
KD, 2 10 5 nM (where KD indicates the equilibrium dissoci-
ation constant), which could not be associated with any precise
binding domain at this stage, although it was plausible that the
two binding sites were HBD1 and HBD2. To substantiate this
assumption, binding experiments were performed after satu-
rating surface-bound FN with 1 mM heparin; this presatura-
tion step prevented any significant binding of rh-sCD157 (Fig.
3A, *).To further corroborateour evidence,CD157bindingexper-
iments were replicated independently on surface-bound HBD1
and HBD2. In both cases, monophasic time course sensorgrams
were observed (Fig. 3, B and C), with KD, HBD1 and KD, HBD2
being 48 17 and 5 3nM, respectively (Fig. 3E). Presaturation
of bothHBDs with heparin hindered any binding of rh-sCD157
(Fig. 3, B, *, and C, *), ruling out the existence of a second
CD157-binding site in HBD2 not blocked by heparin. It is note-
worthy that rh-sCD157 was shown to target HBDs both in full-
length and fragmented FN with comparable affinity, confirm-
ing that no other FN regions were significantly involved in the
binding events. Finally, theCBD fragmentwas immobilized and
used as a negative control for binding; negligible responseswere
obtained upon addition of rh-sCD157 (0.2–0.6 M range), as
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FIGURE 3. Analysis of binding of rh-sCD157 to immobilized fibronectin and its proteolytic fragments by surface plasmon resonance. IAsys binding
curves for the interaction of rh-sCD157 with full-length FN, HBD1, and HBD2 immobilized to the surface of a carboxymethyl dextran sensor. Increasing
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the experimental curve fits.
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inferred from the affinity of the complex, which was more than
2000-fold lower with respect to HBD-CD157 complexes and
comparable with that of BSA-CD157 complexes (Fig. 3D).
Next, we determined the kinetic parameters of rh-sCD157
binding to FN. The calculation of association (ka) and dissoci-
ation (kd) rate constants further dissected the mechanistic
properties of their macromolecular recognition process. The
interaction between rh-sCD157 and FN was characterized by
preferential association kinetics to HBD2; indeed, the associa-
tion rate at the HBD2 site was 6-fold higher compared with the
association at HBD1. In contrast, the dissociation kinetics were
comparable. Therefore, the difference in terms of KD (FN-
HBD1  60  29 nM versus FN-HBD2  10  5 nM) could be
uniquely attributed to the association phase. This behavior was
confirmed with isolated HBDs, with major differences existing
only in ka values (Fig. 3E). It is important to note that differ-
ences in association kinetics were observed between HBD1 in
the context of full-length FN and isolated HBD1. These results
revealed that neighboring domains in full-length FN hindered
recognition of rh-sCD157, an effect that was otherwise hidden
in the equilibrium studies.
To demonstrate that the FN-CD157 interaction was not
influenced by the conformation of FN and HBDs after immo-
bilization, reverse binding experiments were performed on sur-
face-bound rh-sCD157 (Fig. 4, A–C). Kinetic analysis revealed
that ka values were fully comparable with those of the original
binding experiments, whereas kd valuesweremore than 10-fold
higher (Fig. 4D). Based on this evidence,we can reasonably infer
that the binding interface of immobilized rh-sCD157 was avail-
able for interaction with soluble FN and HBDs and that the
destabilization of the complexes mainly relied upon steric hin-
drance (likely due to the proximity to the surface). This hinder-
ing effect was more evident with FN (Fig. 4).
Analysis of the Contribution of CD157 Glycosylation to
Fibronectin Binding—CD157 is a glycoprotein with fourN-gly-
cosylation sites (26). To assess the implications of the glycosidic
chains in the CD157-FN interaction, SPR analysis was per-
formed using increasing concentrations of recombinant His-
tagged CD157 produced in Escherichia coli (Fig. 5; range 10.1
nM to 0.71M, corresponding to 300 ng/ml to 20g/ml). These
analyses revealed that nonglycosylated b-rhCD157 maintained
the ability to selectively bind to HBDs of FN (Fig. 6, A–C) but
not to CBD (Fig. 6D). A slight reduction in binding affinity was
observed comparedwith glycosylated rh-sCD157; in particular,
the KD was	3- and	2-fold lower for HDB1 and for HBD2 in
full-length FN and	5-fold lower for isolated HBDs (Fig. 6E).
Kinetic analysis indicated that the carbohydratemoieties dif-
ferentially affect formation and stabilization of the CD157-
HBD1 or CD157-HBD2 complexes. Specifically, glycosylation
had a modest impact on the recognition process, with a maxi-
mal 2-fold increase in kinetic association constants (with the
only exception of HBD1 within FN), possibly in virtue of favor-
able electrostatic interactions across the CD157-HBDs inter-
face (Fig. 6E). Glycosylation did not significantly affect the
kinetic dissociation constants of HBD2. The kinetic dissocia-
tion constants of HBD1 were up to 10-fold higher in the pres-
ence of b-rhCD157 than of rh-sCD157, indicating that the
observed lower affinity of nonglycosylated CD157 for HBD1
(both isolated and within FN) is largely due to the significant
kinetic destabilization of the complex. These findings suggest
that, although not required for CD157 binding, glycosylation
contributes to stabilize binding thanks to its dynamic proper-
ties and flexibility.
CD157 Binds to Selected ECM Proteins—The ECM is com-
posed of two main classes of macromolecules, fibrous proteins
(such as fibronectin, collagen, laminin, among others) and pro-
D
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FIGURE 4.Reversebinding analysis of FNand its proteolytic fragments to immobilized rh-sCD157by surfaceplasmon resonance. IAsys-binding curves
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sensor. Their association was monitored over time. D, table of binding kinetics values (ka, kd, and KD reported as the means  S.E.) determined from the
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teoglycans (16), which are proteins covalently attached to one
or more glycosaminoglycan chains. Numerous ECM proteins
contain heparin-binding domains (27). Therefore, we investi-
gated CD157 binding to heparin-binding domains in ECMpro-
teins other than FN. Solid-phase binding assays were carried
out inmicrotiter plates coatedwith either FB, Coll I, Vn, or LM,
all of which contain at least one HBD. rh-sCD157 bound to
immobilized FB, LM, and Coll I but not to Vn or gelatin used as
control. No significant binding was observed to polysaccharide
components of the ECM (such as heparin and hyaluronic acid)
(Fig. 7). Binding of rh-sCD157 to FB, LM, and Coll I was con-
centration-dependent (Fig. 8, A–C). The specificity of these
interactions was strengthened by binding competition experi-
ments performed in the presence of anti-CD157mAbs. Indeed,
addition of the RF3 mAb to the assay consistently inhibited the
binding of rh-sCD157 to FB, LM, and Coll I-coated plates.
Addition of SY/11B5 or Mo5 mAbs reduced rh-sCD157 bind-
ing to LMandColl I, respectively (Fig. 8,D–F).Moreover, bind-
25
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ing of saturating concentrations (100 ng/ml) of rh-sCD157 to
FB, LM, and Coll I performed in the presence of increasing
concentrations of heparin showed a consistent dose-depen-
dent, heparin-mediated inhibition. No significant interference
was detected with hyaluronic acid used as control (Fig. 8,G–I).
These findings indicate thatCD157 bindsmultiple ECMpro-
teins at their heparin-binding sites and rule out the existence of
a direct binding between rh-sCD157 and heparin, corroborat-
ing the results obtained by SPR. The absence of glycosamino-
glycans attached to sCD157 (28) or to the rh-sCD157 used in
this study (Fig. 9) allowed us to exclude a contribution of hepa-
ran sulfate in mediating the interaction between CD157 and
ECM.
CD157 Regulates Mesothelial Cell Adhesion to Fibronectin—
To confirm that the interaction between CD157 and FN
observed in vitro using purified proteins was biologically signif-
icant in a cellular context, we used Met-5A non-neoplastic
human pleuralmesothelial cells that expressmembraneCD157
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as an in vitro experimentalmodel.Met-5A cells adhered to both
FN and HBD1, although with different efficiencies, and to
HBD2 with poor efficiency (Fig. 10A).
To investigate whether native membrane-bound CD157 and
purified rh-sCD157 recognize the same binding sites, adhesion
of Met-5A cells to FN and HBD1 was assessed after saturation
of each immobilized protein with rh-sCD157. rh-sCD157 con-
sistently reducedMet-5A cell adhesion to FN andHBD1 and to
other ECMproteins containing the binding site for rh-sCD157,
such as Coll I (Fig. 10B). This suggested that native membrane-
bound CD157 and rh-sCD157 likely share the same binding
site(s). The involvement of CD157 in ECM-mediated cell adhe-
sion was confirmed by the ability of RF3 anti-CD157 mAb (but
not of isotype-matched mouse IgG) to significantly inhibit
Met-5A cell adhesion to FN and HBD1 (Fig. 10, C and D). As
expected, cell adhesion to FNwas also inhibited by neutralizing
antibodies to integrin 1/CD29 and integrin v/CD51. How-
ever, combined block of CD157 and CD29 or CD51 did not
further increase inhibition of Met-5A cell adhesion (Fig. 10C).
Blocking CD157 did not significantly perturb Met-5A cell
adhesion toVn nor increase the inhibitory effect of neutralizing
antibody to 1/CD29 or v/CD51 integrins (Fig. 10E). To con-
clusively prove a role of membrane-bound CD157 in the con-
trol of cell adhesion to ECM proteins, Met-5A cells were trans-
duced with an shRNA that targeted the CD157 mRNA,
resulting in efficient knockdown of CD157 mRNA and protein
expression (Met-5A/shCD157), or with a control shRNA (Met-
5A/scramble) (Fig. 11,A andB). In cells adhering to fibronectin,
loss of CD157 caused changes in F-actin cytoskeleton organi-
zation andmarked reduction in cell spreading and lamellipodia
formation (Fig. 11C). Next, we compared the ability of CD157-
positive and CD157-negativeMet-5A cells to adhere to FN and
to its HDBs and CBD to Coll I, LM, and Vn. Silencing of CD157
resulted in reduced adhesion of Met-5A cells to FN and to
HBD1, but it had no appreciable effect on cell adhesion to CBD
(mainly mediated through integrin engagement). Adhesion of
Met-5A cells to HBD2, although limited (Fig. 10A), was further
reduced by the loss of CD157 (Fig. 11D). Impaired adhesion of
Met-5A/shCD157 cells compared with control cells was also
observedwithColl I and LMbut not Vn (Fig. 11E). The reduced
adhesive capacity of CD157-negative cells was not attributable
to different expression of a set of integrins (Fig. 11F). These
findings support the notion that CD157 plays a direct role in
cell adhesion to FN, LM, and Coll I but not to Vn.
CD157-Fibronectin Interaction Modulates the Transduction
of Intracellular Signals—In addition to its activity in promoting
cell adhesion and migration (8), CD157 cross-linking by spe-
cific mAbs has been shown to elicit a signaling cascade that
involves the phosphorylation of FAK (14, 29, 30). Moreover,
CD157 is part of the integrin-driven molecular machinery that
regulates fundamental functions in neutrophils andmonocytes
through the activation of a complex signaling network (10, 11).
The ability of CD157 to bind FN suggests that this interaction
could account for the receptor activity attributed to CD157.
Hence, we investigated cell signaling events triggered by FN
binding to CD157-positive or CD157-negative Met-5A cells. It
is known that integrin binding to FN rapidly activates FAK by
phosphorylation of Tyr-397 leading to recruitment of SRC and
subsequent activation of the FAK-SRC signaling complex (31).
Western blot analysis of cell extracts, obtained after incubating
the cells for 1 h onFN, showed reduced FAKphosphorylation at
Tyr-397 and an appreciable (although not statistically signifi-
cant) decrease in phosphorylation of c-SRC in Met-5A/
shCD157 cells compared with Met-5A/scramble cells. The
absolute amount of FAK or c-SRC proteins was comparable.
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FIGURE 10. CD157 controls the adhesion of mesothelial cells to extracel-
lular matrix proteins. A, Met-5A cells were plated on full-length fibronectin
or on its proteolytic fragments for 2 h. B, ability of membrane CD157 and
rh-sCD157 to bind the same sites on FN, HBD1, and Coll I was evaluated by
assessing the adhesion efficiency ofMet-5A cells to each protein after satura-
tionwith rh-sCD157 (100 ng/ml). Results are expressed as percentage of con-
trols (cell adhesion to coated proteins without saturation with rh-sCD157
100%,white histogram). ***,p 0.001; **,p 0.01, unpaired t test.C–E, ability
of membrane CD157 to bind full-length fibronectin, HBD1, and Vn was eval-
uated in the presence or absence of the RF3 anti-CD157, anti-CD29, or anti-
CD51blockingmAbs (either aloneor in combination) or irrelevantmurine IgG
(10g/ml). Results are expressed as percentage of control (number of adher-
ent cells in the absence of antibody 100%,white histogram). ***, p 0.001;
**, p 0.01; *, p 0.05, ns, not significant, ANOVAwith Bonferroni’s multiple
comparison test. Cells were plated for FN, HBD1, Coll, or Vn, and then adher-
ent cellswere fixedwith 4%PFA, stainedwith 0.5%crystal violet, and counted
by lightmicroscopy in five randomly selected fields (4) for eachwell. Results
represent the mean values S.E. of at least three experiments performed in
triplicate.
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Moreover, the attenuated phosphorylation of the serine/threo-
nine kinase Akt (a key downstream effector of p110 PI3K) indi-
cated reduced phosphorylation of the downstream PI3K/Akt
pathway inMet-5A/shCD157 compared with control cells (Fig.
12, A and B).
These results show that engagement of CD157 by fibronectin
increases the activation of key adhesion-dependent tyrosine
kinases mirroring the effects observed upon CD157 antibody
cross-linking (11).
DISCUSSION
Soon after the identification of CD157/BST-1 as a NAD-me-
tabolizing ectoenzyme (EC 3.2.2.5) (32), it became clear that
overexpression of CD157 (30) or its clustering by specific
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(bottom panel) of Met-5A cells transduced with a CD157-specific shRNA. -Actin was used as loading control. C, CD157 knockdown-induced changes in cell
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FACSCalibur flow cytometer and CellQuest software. Ten thousand cells were considered for each analysis. x axis fluorescence intensity (FL-1 height), and y
axis number of cells (events).
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monoclonal antibodies (8) induced a variety of cellular
responses, including changes in cell adhesion and migration.
These effects can be attributed to the ability of CD157 to act as
a receptor (29, 33, 34). However, the nature of the physiological
interaction(s) implementing these multiple biological activities
remained an unresolved issue. The identification of the inter-
action between CD157 and ECM achieved in this study thus
provides valuable insights into the biological mechanism
responsible for the nonenzymatic functions of CD157 in phys-
iological conditions and in specific pathological contexts.
Using solid-phase immunoenzymatic and SPR assays, we
demonstrated that purified CD157 specifically binds the extra-
cellular protein fibronectin at itsN-terminal (HBD1) andC-ter-
minal (HBD2) heparin-binding domains. The equilibrium dis-
sociation constants (KD) in the nanomolar range highlight the
fact that the interaction between CD157 and FN at both HBD1
andHBD2 is very strong (far stronger than that of heparin (35))
and that CD157 binds to HBD2 with a KD value	6-fold higher
than toHBD1.The interaction betweenCD157 and theHBDs is
mediated by the protein core, although the glycosidic chains
contribute to stabilize the interaction.
In addition to FN, CD157 bound Coll I, FB, and LM. This
binding was consistently and specifically inhibited by heparin
and by selected CD157-specific mAbs. However, the differen-
tial ability of each mAb to inhibit CD157 binding to discrete
ECM proteins observed in this study cannot be considered a
general rule and cannot be extrapolated to different experimen-
tal contexts. Indeed, antibodies apparently unable to inhibit the
interaction between purified CD157 and ECM proteins (for
example, the SY/11B5 mAb), effectively interfered with adhe-
sion of CD157-positive normal or neoplastic cells to fibronec-
tin, laminin-1, and collagen I (11, 12), a situation that more
faithfully recapitulates the complexity of cell-ECM interaction
occurring in vivo.
The lack of CD157 binding to vitronectin indicates that the
presence of a heparin-binding domain within an ECM protein
is not sufficient to warrant CD157 binding, at least in vitro.
Despite some common characteristics, HBDs differ widely in
structure, and it is conceivable that the CD157-binding site fits
some HBDs but not all. The specific amino acid sequences or
spatial arrangement of amino acids within theHBDs critical for
interaction with CD157 remain to be defined and deserve fur-
ther investigation.
Binding competition experiments have enabled us to further
narrow the binding sites, highlighting that CD157 interacts
with the N-terminal FN1(1–3)motifs comprising the low affin-
ity binding site for heparin, and with the C-terminal type
III(13–14) motifs, which accounts for nearly all the heparin
binding activity (36, 37). The interaction between CD157 and
HBDs of fibronectin that occurs in vitro using purified proteins
reflects physiological interactions driving specific biological
functions in live cells. Indeed, membrane CD157 expressed by
Met-5A mesothelial cells interacts with FN, and anti-CD157
mAbs significantly reduce cell binding to FN and its HBD1,
confirming previous observations (11, 12). The ability of rh-
sCD157 to significantly reduce the binding of Met-5A cells to
FN suggests that native membrane-anchored and recombinant
soluble CD157 share the same binding sites. However, we can-
not exclude that rh-sCD157 affects cell adhesion by interfering
with the binding of other cell surface proteins (such as syn-
decans) to the heparin-binding domains.
The functional relevance of a direct molecular interaction
between CD157 and HBDs has been further substantiated by
the observation that loss of CD157 expression in Met-5A cells
reduced cell spreading and lamellipodia formation and altered
the organization of the matrix-proximal F-actin cytoskeleton.
These changes impaired cell adhesion to FN,Coll I, andLM, but
not toCBDof FNor toVn, inMet-5A/shCD157 comparedwith
Met-5A/scramble cells. This result conclusively demonstrates
that CD157 contributes to cell adhesion through its interaction
with the HBDs located within selected ECM proteins. As
expected, CD157 knockdown did not completely prevent cell
adhesion to ECM proteins because of the existence of compen-
satorymolecular interactions that dampen the effects of CD157
deficiency. Notably, the opposite effects were observed in ovar-
ian cancer cells in which exogenous expression of CD157
resulted in increased cell spreading and cytoskeletal organiza-
tion, leading to improved tumor cellmotility and dissemination
(15).
It has been documented that, despite being a glycosylphos-
phatidylinositol-anchored protein, CD157 acts as a receptor
because it is part of a multimolecular complex ruled by integ-
rins (10, 11). However, how CD157 became part of this molec-
ular complex in physiological and pathological situations was
unclear. The results of this study fill this gap, suggesting that
fibronectin can drive the formation of this complex. FN (like
other ECMmolecules), by virtue of its ordered domain organi-
zation and its simultaneous interaction with a variety of pro-
teins (including integrins and CD157), can promote the re-or-
ganization of multimolecular complexes in the plane of the
membrane, thus driving orderly juxtaposition of different
receptors that orchestrate and integrate the intracellular signal-
ing network that determine cell fate.
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FIGURE 12. CD157 binding to FN induces FAK and c-SRC activation. A,
Met-5A/scramble and Met-5A/shCD157 were starved overnight and plated
for 1 h at 37 °C onto FN-coated plates. Adherent cells were lysed, and cleared
lysates were subjected to Western blot. Membranes were first probed with
anti-phospho-FAK, phospho-c-SRC, or phospho-Akt, stripped, and re-probed
with anti-FAK, -c-SRC, or -Akt, followed by incubation with the appropriate
HRP-conjugatedantibodies.B, phosphorylationof FAK, c-SRC, andAkt inMet-
5A/shCD157 compared withMet-5A/scramble was quantified using the soft-
ware package ImageJ 1.43 (National Institutes of Health). Results are the
means  S.E. of three experiments and are expressed as fold decrease in
phosphorylation in Met-5A/shCD157 compared with control cells (Met-5A/
scramble,white histograms). **, p 0.01; *, p 0.05, unpaired t test.
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CD157 (like many other glycosylphosphatidylinositol-an-
chored proteins (38)) is associated with membrane microdo-
mains known as lipid rafts (11); therefore, the concomitant
engagement of CD157 and integrin receptors by FNwill recruit
integrins inside lipid rafts and bring them in close contact with
CD157. Lipid rafts are enriched in signal transduction mole-
cules (39); hence, the CD157-FN interaction is instrumental to
the delivery of synergistic signals leading to optimal cell adhe-
sion and migration. Consistent with this assumption, knock-
down of CD157 inMet-5A cells remarkably reduced the induc-
tion of fibronectin-mediated phosphorylation of FAK, SRC,
and Akt tyrosine kinases and eventually led to impaired cell
adhesion and spreading.
It is tempting to predict that the broad interaction of CD157
with several ECM proteins may be responsible for many of the
biological effects exerted by CD157 in different physiological
(e.g. leukocyte trafficking) and pathological contexts (e.g.
inflammatory diseases and cancer), where the composition of
the extracellular matrix dictates the final outcome. For exam-
ple, in ovarian cancer, the CD157-ECM interaction occurring
in the peritoneal cavity rescues cells from anoikis and promotes
their migration and metastatic dissemination, ultimately
enhancing tumor aggressiveness (15).
Accumulating evidence implicates tumor cell-ECM interac-
tion in many aspects of tumor biology, including tumor growth
and metastatic spread (40, 41). Hence, it is reasonable to envi-
sion that hindering the interaction between CD157 and
fibronectin (or other ECM proteins depending on a specific
microenvironment) may represent a promising new avenue for
the design of therapeutic strategies to treat inflammation and
ovarian cancer.
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